Group 4B: HR+ Breast Cancer; Targeted Therapies; Clinical Trials; Treatment Resistance

Poster #1065: Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis.

Poster #TPS1126: Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study.

Date

Jun 13 2024

Time

10:00 am - 11:30 am

Zoom Webinar

Category
REGISTER